Silo Pharma, Inc. Common Stock
SILOSilo Pharma, Inc. (SILO) is a biopharmaceutical company focused on developing and commercializing treatments for neurodegenerative and rare brain diseases. The company emphasizes leveraging its expertise in psychiatric and neurological disorders to advance innovative therapies, often through strategic partnerships and acquisitions.
Company News
Silo Pharma announced that its subsidiary QwikAgents has been accepted into Advanced Micro Devices' AMD AI Developer Program. The acceptance provides access to AMD Developer Cloud credits, AI development tools, and technical resources to support QwikAgents' next-generation AI agent platform designed for individuals, developers, small businesses, ...
U.S. stock futures rose on Tuesday as investors awaited Trump's deadline regarding Iran's Strait of Hormuz. UnitedHealth Group surged 6.86% following favorable Medicare Advantage payment rates, while Silo Pharma jumped 45.31% on a patent approval for PTSD treatment. Phillips 66 declined 0.75% due to reported losses from rising oil prices amid geo...
Silo Pharma has initiated a strategic partnership with Fireblocks to develop an institutional-grade infrastructure for managing digital assets, leveraging Fireblocks' secure digital asset custody and transfer capabilities.
Silo Pharma announced positive results from an initial study of its SP-26 ketamine extended-release implant for chronic pain and fibromyalgia, with no serious side effects observed. The company expects final safety and absorption data in March 2025.
Silo Pharma is making progress in developing its lead assets SPC-15 and SP-26 for the treatment of PTSD, stress-induced anxiety, and chronic pain. The company is preparing to submit an IND for SPC-15 in 2025 and is advancing animal studies for SP-26 ketamine implants.
